MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Its lead program, ML-007C-MA, is an oral fixed-dose combination of the investigational M1/M4 muscarinic agonist ML-007 co-formulated with a peripherally acting anticholinergic to activate CNS M1 and M4 receptors while mitigating peripheral cholinergic side effects. ML-007C-MA is designed to synchronize the pharmacokinetics of the agonist and antagonist components to drive efficacy and reduce peripheral side effects. MapLight is advancing ML-007C-MA through ongoing Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. The financing will also fund exploration of other potential indications for ML-007C-MA and the continued advancement of other clinical and preclinical pipeline programs. MapLight's discovery platform aims to identify neural circuits causally linked to disease and target those circuits for therapeutic modulation. MapLight Therapeutics is a clinical-stage biopharmaceutical company using a proprietary discovery platform to identify misfiring neural circuits and target them with precision therapeutics. Led by CEO and founder Christopher Kroeger and based in San Francisco, the company focuses on novel, targeted treatments for brain disorders. Its lead program, ML-007C-MA, is a novel M1/M4 muscarinic agonist combined with a precision-matched peripheral muscarinic antagonist. The company also has ML-007 under study for dyskinesia and ML-004, a 5HT-1b agonist, in Phase 2 for social communication deficits in autism spectrum disorder. Preclinical assets include ML-016, a GPR-6 antagonist for Parkinson’s disease and depression, and ML-009 for hyperactivity and impulsivity. The recent financing strengthens the company’s ability to advance multiple clinical and preclinical programs.

Total raised

$598M

Funding rounds

2

Latest round

Series D

Latest activity

Jul 2025